BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• Affimed to Present at Upcoming Investor Events - Feb 08, 2022

  Affimed N.V. announced that management will present and host one-on-one meetings at the following investor conferences during the month of February 2022.

  February 8, 2022

   · 

  1 min read
• Business

  Merakris and Dept. of Veterans Affairs Sign CRADA Agreement – Clinical Trial for Dermacyte® Wound Care Product To Begin Soon

  Merakris Therapeutics announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs (VA) to test its investigational drug product, Dermacyte® Amniotic Wound Care Liquid.

  February 8, 2022

   · 

  4 min read
• Business

  CENTOGENE Announces CFO Transition and Appointment of Miguel Coego Rios as EVP Finance & Legal and Interim CFO

  Centogene N.V. today announced plans for the transition of Chief Financial Officer René Just and the appointment of Miguel Coego Rios as Executive Vice President of Finance & Legal and Interim CFO. René Just has resigned from the Company effective March 31, 2022.

  February 8, 2022

   · 

  6 min read
• Business

  Caris’ Precision Oncology Alliance Welcomes The Ohio State University Comprehensive Cancer Center

  Caris Life Sciences announced today that the The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has joined Caris’ Precision Oncology Alliance™ (POA).

  February 8, 2022

   · 

  6 min read
• Pharm Country

  Immunic, Inc. to Participate in Investor and Scientific Conferences in February

  Immunic, Inc. today announced participation in the following investor and scientific conferences in February.

  February 8, 2022

   · 

  5 min read
• Business

  Alfred W. Sandrock, Jr., M.D., Ph.D., Joins Verge Genomics’ Board of Directors

  Verge Genomics announced today that Alfred W. Sandrock, Jr., M.D., Ph.D., has been appointed to its Board of Directors.

  February 8, 2022

   · 

  4 min read
• Cingulate Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for Attention Deficit/Hyperactivity Disorder (ADHD)Expedited Clinical Program Reduces Capital Requirements

  Cingulate Inc. today announced updates to its 2022 clinical program for its lead candidate CTx-1301, an investigational asset for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).

  February 8, 2022

   · 

  5 min read
• Biotech Beach

  Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome

  Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced positive topline results from the endpoint clinical trial of its InFoods® IBS diagnostic-guided therapy.

  February 8, 2022

   · 

  8 min read
• Business

  Pfizer Reports Fourth-Quarter and Full-Year 2021 Results

  Pfizer Inc. (NYSE: PFE) reported strong financial results for fourth-quarter and full-year 2021 and provided 2022 total company financial guidance(4).

  February 8, 2022

   · 

  68 min read
• Business

  Merck and Ridgeback Announce That 3.1 Million Courses of Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Have Been Supplied to the U.S. Government for Use in the United States

  Merck and Ridgeback Biotherapeutics today announced that a total of approximately 3.1 million courses of molnupiravir have been provided to the U.S. government for allocation across the country.

  February 8, 2022

   · 

  17 min read